Skip to search.
 TSX Up 0.11% TSX Ventures Down 0.09%

More On TTHI

Quotes

Charts

News & Info

Company

  • Profile
  • Key Statistics
  • SEC Filings
  • Competitors
  • Industry
  • Components

Analyst Coverage

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials

  • Income Statement
  • Balance Sheet
  • Cash Flow

Transition Therapeutics Inc. (TTHI)

-NasdaqGM
0.00 0.00(0.00%) N/A
Prev Close:N/A
Open:N/A
Bid:N/A
Ask:N/A
1y Target Est:1.77
Beta:2.38689
Next Earnings Date:N/A
Day's Range:N/A - N/A
52wk Range:0.66 - 2.75
Volume:0
Avg Vol (3m):86,277
Market Cap:N/A
P/E (ttm):N/A
EPS (ttm):-0.49
Div & Yield:N/A (N/A)
Quotes delayed, except where indicated otherwise. Currency in USD.

Headlines

Key Statistics

Forward P/E (1 yr):N/A
P/S (ttm):N/A
Ex-Dividend Date:N/A

Analysts

Annual EPS Est (Jun-16) :-0.33
Quarterly EPS Est (Sep-15) :N/A
Mean Recommendation*:3.0
PEG Ratio (5 yr expected):N/A

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

Transition Therapeutics Inc., a biopharmaceutical company, researches and develops therapeutic agents for disease indications primarily in Canada. The company's lead central nervous system drug candidate is ELND005, which has completed a Phas... View More
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback